IL164734A0 - Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof - Google Patents

Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof

Info

Publication number
IL164734A0
IL164734A0 IL16473404A IL16473404A IL164734A0 IL 164734 A0 IL164734 A0 IL 164734A0 IL 16473404 A IL16473404 A IL 16473404A IL 16473404 A IL16473404 A IL 16473404A IL 164734 A0 IL164734 A0 IL 164734A0
Authority
IL
Israel
Prior art keywords
derivatives
carboxylic acids
sub
site
action
Prior art date
Application number
IL16473404A
Other languages
English (en)
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of IL164734A0 publication Critical patent/IL164734A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
IL16473404A 2002-05-14 2004-10-20 Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof IL164734A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38064102P 2002-05-14 2002-05-14

Publications (1)

Publication Number Publication Date
IL164734A0 true IL164734A0 (en) 2005-12-18

Family

ID=29549994

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16473404A IL164734A0 (en) 2002-05-14 2004-10-20 Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof

Country Status (16)

Country Link
US (2) US7355047B2 (cg-RX-API-DMAC7.html)
EP (1) EP1503759B1 (cg-RX-API-DMAC7.html)
JP (1) JP4532263B2 (cg-RX-API-DMAC7.html)
KR (1) KR20040107525A (cg-RX-API-DMAC7.html)
CN (1) CN1652784A (cg-RX-API-DMAC7.html)
AT (1) ATE417613T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003229043B2 (cg-RX-API-DMAC7.html)
BR (1) BR0309965A (cg-RX-API-DMAC7.html)
CA (1) CA2484308A1 (cg-RX-API-DMAC7.html)
DE (1) DE60325347D1 (cg-RX-API-DMAC7.html)
DK (1) DK1503759T3 (cg-RX-API-DMAC7.html)
ES (1) ES2319176T3 (cg-RX-API-DMAC7.html)
IL (1) IL164734A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA04011156A (cg-RX-API-DMAC7.html)
NZ (1) NZ536061A (cg-RX-API-DMAC7.html)
WO (1) WO2003097564A2 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040107525A (ko) * 2002-05-14 2004-12-20 더 리전트 오브 더 유니버시티 오브 캘리포니아 치환된 퀴놀론 카르복실산, 이들의 유도체, 그의 작용부위 및 용도
US7470706B2 (en) 2004-01-31 2008-12-30 Sanofi-Aventis Deutschland Gmbh Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
DE102004004971B3 (de) * 2004-01-31 2005-09-15 Aventis Pharma Deutschland Gmbh Cycloalkyl substituierte 7-Amino-4-chinolon-3-carbonsäure-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arnzeimittel
AU2005240657A1 (en) * 2004-05-06 2005-11-17 The Regents Of The University Of California Substituted enaminones, their derivatives and uses thereof
US8354427B2 (en) * 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
BR122018075478B8 (pt) 2004-06-24 2023-10-31 Vertex Pharma moduladores de transportadores de cassete de ligação de atp
JP4796622B2 (ja) * 2005-04-11 2011-10-19 エフ．ホフマン−ラ ロシュ アーゲー （３，４−ジヒドロ−キナゾリン−２−イル）−インダン−１−イル−アミン
AU2006243244A1 (en) * 2005-05-04 2006-11-09 F. Hoffmann-La Roche Ag (3,4-dihydro-quinazolin-2-yl)-(2-aryloxy-ethyl)-amines having an activity on the 5-HT receptor
AU2006322045A1 (en) * 2005-12-05 2007-06-14 Merck & Co., Inc. Quinolone M1 receptor positive allosteric modulators
EP1979367A2 (en) * 2005-12-24 2008-10-15 Vertex Pharmaceuticals Incorporated Quinolin-4-one derivatives as modulators of abc transporters
HUE032813T2 (en) 2005-12-28 2017-11-28 Vertex Pharma Solid forms of N- [2,4-bis (1,1-dimethyl ethyl) -5-hydroxyphenyl] -1,4-dihydro-4-oxoquinoline-3-carboxamide
EP2013182B1 (en) * 2006-03-13 2013-09-04 Kyorin Pharmaceutical Co., Ltd. Aminoquinolones as gsk-3 inhibitors
CA2660421A1 (en) * 2006-08-10 2008-02-14 Ferrer Internacional S.A. 1h-quinolin-4-one compounds, with affinity for the gaba receptor, processes, uses and compositions
EP1886996A1 (en) * 2006-08-10 2008-02-13 Ferrer Internacional, S.A. 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions
NZ576036A (en) 2006-10-16 2010-10-29 Bionomics Ltd Naphthyridine containing compounds for treating anxiety disorders
US10954231B2 (en) 2006-10-16 2021-03-23 Bionomics Limited Anxiolytic compounds
WO2009040377A2 (en) * 2007-09-27 2009-04-02 Ge Healthcare Limited Imaging agents
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
JP2012506857A (ja) * 2008-10-23 2012-03-22 メルク・シャープ・エンド・ドーム・コーポレイション 縮合複素環式ｍ１受容体ポジティブアロステリック調節因子
HUE035160T2 (en) 2009-03-20 2018-05-02 Vertex Pharma Process for making modulators of cystic fibrosis transmembrane conductance regulator
US20120093917A1 (en) * 2009-04-02 2012-04-19 Robert Hromas Metnase and intnase inhibitors and their use in treating cancer
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
CA2828780A1 (en) 2011-03-02 2012-09-07 Bionomics Limited Novel small-molecules as therapeutics
AU2012222869B2 (en) * 2011-03-02 2015-08-13 Bionomics Limited Methods of treating a disease or condition of the central nervous system
US9133188B2 (en) 2011-05-12 2015-09-15 Bionomics Limited Methods for preparing naphthyridines
CA2865519C (en) 2012-02-27 2018-01-02 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions comprising a solid dispersion of n-[2,4-bis(1,1-dimethylethyl0-5-hydroxyphenyl-1]-1,4-dihydro-4-oxoquinolone-3-carboxamide for treating cystic fibrosis
EP3204358B1 (en) 2014-10-07 2018-09-19 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
CN107501107A (zh) * 2017-09-26 2017-12-22 兰亚朝 喹诺酮药物的中间体合成方法
CN111269131B (zh) * 2020-03-12 2021-12-28 江苏飞宇医药科技股份有限公司 以三正丙胺为吸酸剂制备环丙乙酯胺化物的工艺

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1433774A (en) * 1973-02-26 1976-04-28 Allen & Hanburys Ltd Heterocyclic compounds apparatus for conveying articles
JPS5715760B2 (cg-RX-API-DMAC7.html) * 1974-06-11 1982-04-01
US4390541A (en) 1980-12-19 1983-06-28 Lilly Industries Limited Quinolone derivatives and their use in a method of controlling an immediate hypersensitivity disease
US6248739B1 (en) * 1999-01-08 2001-06-19 Pharmacia & Upjohn Company Quinolinecarboxamides as antiviral agents
US6413956B1 (en) * 1999-05-06 2002-07-02 Neurogen Corporation Substituted 4-oxo-quinoline-3-carboxamides
GB0127349D0 (en) * 2001-11-14 2002-01-02 Glaxo Group Ltd Macrolides
KR20040107525A (ko) * 2002-05-14 2004-12-20 더 리전트 오브 더 유니버시티 오브 캘리포니아 치환된 퀴놀론 카르복실산, 이들의 유도체, 그의 작용부위 및 용도

Also Published As

Publication number Publication date
BR0309965A (pt) 2005-03-01
US7355047B2 (en) 2008-04-08
EP1503759A2 (en) 2005-02-09
CA2484308A1 (en) 2003-11-27
US20080176897A1 (en) 2008-07-24
HK1072905A1 (en) 2005-09-16
ATE417613T1 (de) 2009-01-15
CN1652784A (zh) 2005-08-10
AU2003229043A1 (en) 2003-12-02
EP1503759B1 (en) 2008-12-17
JP2005535592A (ja) 2005-11-24
AU2003229043B2 (en) 2008-12-04
KR20040107525A (ko) 2004-12-20
MXPA04011156A (es) 2005-02-17
DE60325347D1 (de) 2009-01-29
NZ536061A (en) 2008-09-26
DK1503759T3 (da) 2009-04-14
JP4532263B2 (ja) 2010-08-25
WO2003097564A3 (en) 2004-02-26
EP1503759A4 (en) 2006-02-15
ES2319176T3 (es) 2009-05-05
WO2003097564A2 (en) 2003-11-27
US20060178516A1 (en) 2006-08-10

Similar Documents

Publication Publication Date Title
IL164734A0 (en) Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof
WO2000045799A3 (de) Verwendung von substituierten isoxazolcarbonsäuren und derivaten und neue stoffe
ATE370943T1 (de) Fluoropyrrolidine als dipeptidyl-peptidase inhibitoren
IL162527A0 (en) Novel fluorene carboxylic acid esters, methods forthe production thereof, and use of the same as pharmaceuticals
NO20072767L (no) Gabapentin prodrug vedvarende frigivelse orale doseringsformer
IL158923A0 (en) Fluoropyrrolidines as dipeptidyl peptidase inhibitors
AP2005003418A0 (en) Alpha substituted carboxylic acids as ppar modulators.
ATE380175T1 (de) Pyrrolidine als dipeptidyl peptidase inhibitoren
NO20034920D0 (no) Styrking av terapeutiske virkninger av fettsyrer
AU2003293311A8 (en) Secondary binding site of dipeptidyl peptidase iv (dp iv)
IS7497A (is) (1a,3a,5a)(3-amínómetýl bísýkló[3.2.0]hept-3-ýl)l-ediksýra, lyfjasamsetningar og notkun efnasambands til framleiðslu á lyfjum
AU2002358078A1 (en) Herbicides based on substituted carboxylic acid anilides
WO2003032912A3 (en) Treatment of cns disorders using cns target modulators
AU2003209726A1 (en) Catalyst-precursor for the production of maleic acid anhydride and method for the production thereof
UA85711C2 (ru) Замещенные енаминоны, их производные и их применение
NO20044868L (no) Fremgangsmater for behandling av gastrointestinal og genitourinsmerte forstyrrelser ved bruk av vinlafaxin og derivater
AU2003304226A1 (en) Inhibition of rosin crystallization
AU6689900A (en) 3-arylsulfonyl-2-(substituted methyl)propanoic acid derivates as matrix metalloproteinase inhibitors
DE60216083D1 (de) (OXOPYRAZOLOi1,5AöPYRIMIDIN-2-YL) ALKYLCARBONSÄUREAMIDE
AU2001247233A1 (en) Ppar gamma agonists for the treatment of liver inflammatory disorders
AU2003220106A1 (en) Novel silane modified carboxylic acid substituted amines and salts thereof
AU2003226755A1 (en) Carboxylic acid amides
DE602004003173D1 (de) Verwendung von konjugierter Linolsäure zur Behandlung der Erkältung
WO2003045917A3 (en) Ccr-3 receptor antagonists vii
HK1055059A2 (en) 5-SUBSTITUTED 7,9-DIFLUORO-5H-CHROMENO[3,4-f]QUINOLINE COMPOUNDS AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS